BRACHY:一项评估外照射放疗联合或不联合高剂量率腔内近距离放疗对晚期非小细胞肺癌症状改善的随机试验
这项多中心随机试验将134例有症状的III或IV期非小细胞肺癌伴腔内病变患者随机分配至外照射放疗(EBRT)或EBRT联合高剂量率腔内近距离放疗(HDRIB)。研究因入组缓慢提前关闭;6周时两组患者报告的整体肺癌症状改善比例无显著差异(28.4% vs 29.9%,P=0.84),联合治疗仅对咯血有显著改善(P=0.03),3/4级毒性相似。作者结论认为联合治疗的症状缓解改善小至中等但未达统计学显著,推荐HDRIB前需进一步研究。
要点
- 6周时EBRT组28.4%与EBRT+HDRIB组29.9%患者报告整体肺癌症状改善,差异无统计学意义(P=0.84)。
- 联合治疗仅在咯血改善上达统计学显著(P=0.03),其他个体症状及生存无显著差异。
- 两组3/4级毒性相似;研究因入组缓慢提前关闭(实际入组134例,计划250例)。
核心结论
- 联合治疗在症状缓解方面可见小至中等改善,但未达统计学显著。
- 作者认为在推荐EBRT联合HDRIB用于肺癌症状姑息治疗前需进一步研究。
研究设计与样本
- 多中心随机试验,计划样本量250例,基于症状改善率从40%提升至60%、双侧α=0.05、80%把握度计算。
- 实际随机134例(EBRT组67例,EBRT+HDRIB组67例),4.5年内入组,因入组缓慢提前关闭。
- 纳入有症状的III或IV期非小细胞肺癌伴腔内病变患者;平均年龄69.8岁,67%患者有转移性疾病。
- EBRT方案为20 Gy分5次每日照射1周或30 Gy分10次每日照射2周;HDRIB为14 Gy分2次、间隔1周。
- 主要终点为随机化后6周时患者报告的整体肺癌症状在肺癌症状量表(LCSS)上的改善比例。
主要发现
- 6周时EBRT组19例(28.4%)与EBRT+HDRIB组20例(29.9%)患者经历肺癌症状改善(P=0.84)。
- 限于完成LCSS的患者,症状改善比例分别为40.4%与47.6%(P=0.49)。
- 整体症状的平均变化评分组间差异为0.3-0.5个标准差,方向有利于EBRT+HDRIB,但仅咯血改善达统计学显著(P=0.03)。
- 无进展生存期与总生存期均未观察到显著差异。
- 两组3/4级毒性相似。
关键数值与推荐
- 症状改善主要终点:EBRT组28.4% vs EBRT+HDRIB组29.9%(P=0.84),差异未达统计学显著。
- 完成LCSS者症状改善:EBRT组40.4% vs EBRT+HDRIB组47.6%(P=0.49),差异未达统计学显著。
- 咯血改善:EBRT+HDRIB组较EBRT组显著改善(P=0.03)。
- 整体症状平均变化评分组间差异0.3-0.5个标准差,方向有利于EBRT+HDRIB。
临床怎么用
- 原文结论未给出具体推荐;作者认为在推荐EBRT联合HDRIB用于肺癌症状姑息治疗前需进一步研究。
局限性
- 研究因入组缓慢提前关闭,实际入组134例,低于计划样本量250例。
- 作者结论指出在推荐HDRIB联合EBRT前需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Uncontrolled studies suggest that the addition of high-dose-rate intraluminal brachytherapy (HDRIB) to external beam radiation therapy (EBRT) may improve palliation for patients with advanced non-small cell lung cancer (NSCLC). The purpose of this study was to evaluate the potential clinical benefit of adding HDRIB to EBRT in a multicenter randomized trial. METHODS AND MATERIALS: Patients with symptomatic stage III or IV NSCLC with endobronchial disease were randomized to EBRT (20 Gy in 5 daily fractions over 1 week or 30 Gy in 10 daily fractions over 2 weeks) or the same EBRT plus HDRIB (14 Gy in 2 fractions separated by 1 week). The primary outcome was the proportion of patients who achieved symptomatic improvement in patient-reported overall lung cancer symptoms on the Lung Cancer Symptom Scale (LCSS) at 6 weeks after randomization. Secondary outcomes included improvement in individual symptoms, symptom-progression-free survival, overall survival, and toxicity. The planned sample size was 250 patients based on detection of symptomatic improvement from 40% to 60% with a 2-sided α of .05 and 80% power. RESULTS: A total of 134 patients were randomized over 4.5 years: 67 to each arm. The study closed early owing to slow accrual. The mean age was 69.8 years, and 67% of patients had metastatic disease. At 6 weeks, 19 patients (28.4%) in the EBRT arm and 20 patients (29.9%) in the EBRT plus HDRIB arm experienced an improvement in lung cancer symptoms (P = .84). When limited to patients who completed the LCSS, percentages were 40.4% versus 47.6%, respectively (P = .49). Between group differences in mean change scores (0.3-0.5 standard deviations) in favor of EBRT plus HDRIB were observed for overall symptoms, but only hemoptysis was significantly improved (P = .03). No significant differences were observed in progression-free or overall survival. Grade 3/4 toxicities were similar between groups. CONCLUSIONS: Small to moderate improvements were seen in symptom relief with the combined therapy, but they did not reach statistical significance. Further research is necessary before recommending HDRIB in addition to EBRT for palliation of lung cancer symptoms.
引用
- Sur R, Pond G, Falkson C, et al. BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate Intraluminal Brachytherapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 36610615. doi:10.1016/j.ijrobp.2022.12.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。